Focused on the commercial exploitation of virulence factors from mammalian viruses to create novel therapeutics for autoimmunity and inflammation
Focused on the development and commercialization of prescription human therapeutic products for the treatment of cancer
Maverick Therapeutics is a preclinical stage biotech company founded by MPM that is developing a novel class of T cell- redirecting antibody. Critical to the opportunity, the antibodies are designed to expand the therapeutic index via their conditional activation in the tumor microenvironment.
Developed and commercialized therapeutics for autoimmune diseases.
Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women’s healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne’s focus areas.
Verus Pharmaceuticals, Inc. operates as a pediatric-oriented specialty pharmaceutical company. It identifies, develops, and delivers solutions for the treatment of asthma, allergies, and related diseases and conditions. The company also offers Twinject, an epinephrine auto-injector for anaphylaxis.
Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.
Vaccinogen is a biotechnology company that produces personalized vaccines that use the patient’s immune system to fight the disease.
Theraclone Sciences’ comprehensive screening technology rapidly identifies the rare few antibodies that have evolved to successfully ward off disease. We are working to develop these human monoclonal antibodies as safe and effective therapeutic products.
Tercica, Inc., was a biopharmaceutical company based in Brisbane, California, United States. It developed Increlex (mecasermin [rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1 (rhIGF-1). Tercica applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency (Primary IGFD), which is characterized by growth faiulre, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.
Tercica licensed rights to develop, manufacture, and market Increlex from Genentech, Inc. Increlex conducted Phase III clinical trials to evaluate the safety and efficacy of Increlex in children with Primary IGFD.
In 2008, the Ipsen Group acquired Tercica and changed its name to Ipsen Biopharmaceuticals, Inc.